{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atezolizumab&page=22", "query": { "intervention": "atezolizumab", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 512, "total_pages": 52, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atezolizumab&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atezolizumab&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T10:47:56.943Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04446117", "title": "Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Prostate Cancer", "Prostate Adenocarcinoma" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 575, "start_date": "2020-10-19", "completion_date": "2026-10-16", "has_results": true, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-10-14T10:47:56.943Z", "location_count": 36, "location_summary": "Tucson, Arizona • Duarte, California • Fullerton, California + 30 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Marina del Rey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04446117" }, { "nct_id": "NCT07113691", "title": "Iadademstat + SBRT With Atezo in ES-SCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Extensive Stage Small Cell Lung Cancer (ES-SCLC)" ], "interventions": [ { "name": "Iadademstat", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "SBRT", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2026-01-20", "completion_date": "2030-01", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-14T10:47:56.943Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT07113691" }, { "nct_id": "NCT02543645", "title": "A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Renal Cell", "Kidney Diseases", "Kidney Neoplasms", "Urogenital Neoplasms", "Urologic Diseases", "Urologic Neoplasms", "Neoplasms by Histologic Type", "Neoplasms", "Clear-cell Metastatic Renal Cell Carcinoma", "Melanoma", "Triple Negative Breast Cancer", "Bladder Cancer", "Head and Neck Cancer", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Combination of Varlilumab and Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2015-10", "completion_date": "2017-05-22", "has_results": false, "last_update_posted_date": "2018-04-30", "last_synced_at": "2026-10-14T10:47:56.943Z", "location_count": 4, "location_summary": "San Francisco, California • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02543645" }, { "nct_id": "NCT04696575", "title": "Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extensive Stage Lung Small Cell Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2021-07-02", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2025-12-15", "last_synced_at": "2026-10-14T10:47:56.943Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04696575" }, { "nct_id": "NCT03125902", "title": "A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Triple-Negative Breast Cancer" ], "interventions": [ { "name": "Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody", "type": "DRUG" }, { "name": "Atezolizumab Placebo", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 653, "start_date": "2017-08-25", "completion_date": "2023-01-17", "has_results": true, "last_update_posted_date": "2024-03-26", "last_synced_at": "2026-10-14T10:47:56.943Z", "location_count": 8, "location_summary": "Stanford, California • Fort Myers, Florida • St. Petersburg, Florida + 5 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03125902" }, { "nct_id": "NCT05171777", "title": "A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 179, "start_date": "2022-04-04", "completion_date": "2024-10-25", "has_results": true, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-10-14T10:47:56.943Z", "location_count": 4, "location_summary": "Brick, New Jersey • Massillon, Ohio • Medford, Oregon + 1 more", "locations": [ { "city": "Brick", "state": "New Jersey" }, { "city": "Massillon", "state": "Ohio" }, { "city": "Medford", "state": "Oregon" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05171777" }, { "nct_id": "NCT02304393", "title": "A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Selicrelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2014-12-12", "completion_date": "2019-11-07", "has_results": false, "last_update_posted_date": "2019-12-13", "last_synced_at": "2026-10-14T10:47:56.943Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02304393" }, { "nct_id": "NCT05717400", "title": "Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Liver Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Sofosbuvir", "type": "DRUG" }, { "name": "Velpatasvir", "type": "DRUG" }, { "name": "Voxilaprevir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2023-03-17", "completion_date": "2024-08-29", "has_results": true, "last_update_posted_date": "2024-12-31", "last_synced_at": "2026-10-14T10:47:56.943Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05717400" }, { "nct_id": "NCT03452137", "title": "A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 406, "start_date": "2018-04-03", "completion_date": "2024-03-06", "has_results": true, "last_update_posted_date": "2024-10-09", "last_synced_at": "2026-10-14T10:47:56.943Z", "location_count": 12, "location_summary": "Duarte, California • La Jolla, California • Santa Monica, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03452137" }, { "nct_id": "NCT06551142", "title": "A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Ris-Rez", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Tarlatamab", "type": "BIOLOGICAL" }, { "name": "Dostarlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 845, "start_date": "2024-09-30", "completion_date": "2029-06-08", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-14T10:47:56.943Z", "location_count": 15, "location_summary": "Stanford, California • Denver, Colorado • New Haven, Connecticut + 12 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06551142" } ] }